Editing Novo Nordisk A/S (section)

== <big>Idea</big> ==
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and rare diseases (biopharmaceuticals). The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.<ref>https://www.novonordisk.com/about/our-heritage.html</ref>

Novo Nordisk was founded in 1923 by two Danish brothers, August and Harald Krogh, with the idea of developing and manufacturing insulin for people with diabetes. The company has since grown to become the world's largest insulin producer, responsible for 50% of the world supply, and a leading developer of treatments for other serious chronic diseases, including obesity, haemophilia, and growth disorders.

<u>Mission Statement</u>

Novo Nordisk's mission is to "drive change to defeat serious chronic diseases." The company does this by pioneering scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure the diseases it treats.